MAZE Maze Tx: Company Short-Term Debts

MAZE (Maze Therapeutics Corp) - company brandmark

Catalysts for small molecule progress in combating metabolic dysfunction are only beginning to emerge, while research costs are already priced into the quotes, which stand at 0.01. Price action on the GURU.Markets platform links these factors to the biopharmaceutical environment, where the Compass platform creates a continuous development cycle. Massive investments and patent protection grant Maze Therapeutics Inc (MAZE) exclusive ownership of these technologies.

mazetx.com (MAZE) - Current Liabilities from 02/01/2025 to 11/01/2026

Analytical breakdowns for Maze Therapeutics Corp (MAZE)

- current quotes and average value forecast:
Price Chart Maze Therapeutics|MAZE - Consensus Target
- company stock capitalization data:
Market Capitalization Maze Therapeutics Inc|MAZE - Enterprise Value
- business book valuation details:
Accounting Value per Share Maze Therapeutics|MAZE - Net Asset Value|Market Capitalization to Book Value Ratio mazetx.com|MAZE - Company Assets
- debt level and financial liquidity data:
Total Debt to Equity Ratio Maze Therapeutics Inc|MAZE - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Ratio Maze Therapeutics Inc|MAZE - Company Cumulative Indebtedness|Debts to Book Capitalization Maze Therapeutics Inc|MAZE - Company Long-Term Loans and Borrowings|Company Short-Term Debts Maze Therapeutics|Quick Liquidity mazetx.com
- earnings and valuation multiples indicators:
MAZE - Final Profit
Summary company analytics:Maze Therapeutics (MAZE)
Flagship merchandise of mazetx.com

This indicator reflects the total liabilities of Maze Therapeutics Inc (MAZE) due within the next twelve months. The metric measures current liquidity and the company's ability to service urgent loans without raising new resources. For a biotech startup utilizing the Compass platform, such expenses are critical when funding costly genetic research. By analyzing the volume of short-term debt capital, an investor can assess the business's financial stability. This chart's dynamics allow for the timely diagnosis of cash flow gap risks.

Competing companies

TEM - Company Short-Term Debt|Qiagen NV (QGEN) - Company Current Liabilities|IONS: Company Short-Term Debts|Repligen Inc. (RGEN) - Company Short-Term Debts|Company Current Liabilities RNA|crisprtx.com - Current Liabilities|Company Short-Term Debts WGS|RARE - Short-Term Debt|Beam Therapeutics Corp - Company Current Liabilities|Company Short-Term Loans and Borrowings SRPT|TWST: Company Current Liabilities|10xgenomics.com - Amount of Current Liabilities|NTLA: Company Short-Term Debts|Stoke Therapeutics Inc - Company Short-Term Loans and Borrowings|BLFS (BioLife Corp) - Company Short-Term Debts|Short-Term Debt Wave Pharma WVE|Company Short-Term Debt Sionna Therapeutics Inc (SION)|PRME (primemedicine.com) - Company Short-Term Loans and Borrowings|Company Short-Term Debts TSHA (Taysha Gene Therapies, Inc.)|Company Short-Term Debts uniQure NV QURE|MGTX - Company Short-Term Debt|Current Liabilities RGNX|SLDB: Company Short-Term Debts|Short-Term Debt ocugen.com (OCGN)|Company Current Liabilities PACB|Company Short-Term Debts Benitec Biopharma Inc|Company Current Liabilities DSGN (Design Pharma)|Amount of Current Liabilities RCKT|Company Short-Term Debts FDMT (4D Molecular Therapeutics)|Short-Term Debt Volume Lexeo Therapeutics Inc. (LXEO)|Korro Bio, Inc - Company Short-Term Debts|Editas Medicine Inc (EDIT) - Company Current Liabilities|Silence Therapeutics Inc. (SLN) - Company Short-Term Debt|PRQR - Short-Term Debt Volume|Company Current Liabilities CDXS|SGMO: Company Short-Term Loans and Borrowings|Company Short-Term Debts NAUT|Short-Term Debt Volume Metagenomi Inc.|Company Short-Term Debt Precision BioSciences DTIL|GBIO: Company Short-Term Indebtedness|Boundless Bio, Inc. - Company Short-Term Debts|Exicure, Inc. (XCUR) - Company Current Liabilities|imunon.com (IMNN) - Company Short-Term Debt|Company Current Liabilities Phio Pharmaceuticals Corp.|MBIO (Mustang Bio Inc) - Company Short-Term Debts|Company Short-Term Debts TransCode|Company Current Liabilities BNGO (Bionano Genomics, Inc.)|APDN: Current Liabilities|Company Short-Term Debts BLUE (bluebird bio)|ImmunoPrecise Antibodies Ltd (IPA) - Short-Term Debt|Omega - Company Short-Term Debts|OMIC (Singular Genomics Corp) - Company Short-Term Indebtedness|Regulus Therapeutics (RGLS) - Company Short-Term Debt|Company Short-Term Indebtedness SYRS|TBIO (Telesis Bio) - Company Short-Term Debts|Company Short-Term Debts TRACON Pharmaceuticals Inc.|Company Short-Term Debt Unity Bio (UBX)